Person: BÜLBÜL BAŞKAN, EMEL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
BÜLBÜL BAŞKAN
First Name
EMEL
Name
42 results
Search Results
Now showing 1 - 10 of 42
Publication Psychometric properties of screening instruments for psoriatic arthritis(Bmj Publishing Group, 2023-06-01) Özdede, Ayşe; Ayan, Güzin; Can, Gerçek; Bektaş, Murat; Akdoğan, Nil; Solak, E. Öksüm; Engin, Bahar; Yalıcı-Armağan, B.; Adisen, E. Özsoy; Atakan, N.; Başkan, E. Bülbül; Borlu, M.; Hamuryudan, Vedat; Inanç, Murat; Kiraz, Sedat; Önen, F.; Uğurlu, Serdal; Yaylı, S.; Kalyoncu, U.; Hatemi, Gülen; Yazıcı, Senem; Bülbül, Başkan Emel; BÜLBÜL BAŞKAN, EMEL; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; CEB-8268-2022; HDK-8589-2022Publication Birt-hogg-dube syndrome: Diagnostic journey of three cases from skin to gene(Korean Dermatological Assoc, 2022-02-01) Gül, Şeref; Dilektaşlı, Aslı Görek; GÖREK DİLEKTAŞLI, ASLI; Temel, Şehime Gülsün; TEMEL, ŞEHİME GÜLSÜN; Hasal, Eda; Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Sag, Şebnem Özemri; ÖZEMRİ SAĞ, ŞEBNEM; Adım, Şaduman Balaban; BALABAN ADIM, ŞADUMAN; Tıp Fakültesi; Tıbbi Genetik Ana Bilim Dalı; 0000-0001-6310-5107; 0000-0001-7099-9647; 0000-0002-9802-0880; AAG-8385-2021; AAH-8355-2021Birt-Hogg-Dube syndrome (BHDS) is a rare disorder characterized by the triad of cutaneous lesions, renal tumors, lung cysts and inactivation of the gene folliculin (FLCN). Here, we present three female patients diagnosed with BHDS. First case a 55-year-old female had flesh moles histopathology compatible with angiofibroma, multiple cysts in the lung and kidneys, FLCN gene mutations ('c.1285dupC [p.His429Profs*]' 11th exon and 'c.653G>A [p.Arg258His]' 7th exon). The second case a 76-year-old female had trichodiscoma on her skin, multiple cysts in the lung, spontaneous pneumothorax, FLCN gene mutation 'c.1285dupC (p.His429Profs*27) 11th exon' and, her son had renal carcinoma history under 50 years of age. Our third case, also the daughter of case 2, had dermal papules histopathology compatible with trichodiscoma, spontaneous pneumothorax, FLCN gene mutation 'c.1285dupC (p.His429Profs*27) 11th exon' and, parotid oncocytoma. Through our cases, we document the first case of two mutations ('c.1285dupC [p.His429Profs*]' 11th exon and 'c.653G>A [p.Arg258His]' 7th exon) in the same FLCN gene and the 11th known case of parotid oncocytoma associated with BHDS in the light of the literature.Publication Identification of disease severity(Deri Zuhrevi Hastaliklar Dernegi, 2016-01-01) Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Tıp Fakültesi; Deri ve Zührevi Hastalıkları Ana Bilim Dalı; AAH-1388-2021Publication Investigation of infectious droplet dispersion in a hospital examination room cooled by split-type air conditioner(Springer, 2024-05-08) Yüce, Bahadir Erman; Kalay, Onur Can; Karpat, Fatih; Alemdar, Adem; Temel, Şehime Gülsün; Dilektaşlı, Aslı Görek; Başkan, Emel Bülbül; Özakın, Cüneyt; Coşkun, Burhan; YÜCE, BAHADIR ERMAN; Kalay, Onur Can; KARPAT, FATİH; ALEMDAR, ADEM; TEMEL, ŞEHİME GÜLSÜN; GÖREK DİLEKTAŞLI, ASLI; BÜLBÜL BAŞKAN, EMEL; ÖZAKIN, CÜNEYT; COŞKUN, BURHAN; Tıp Fakültesi; Histoloji ve Embriyoloji Ana Bilim DalıThe novel coronavirus (SARS-CoV-2) outbreak has spread worldwide, and the World Health Organization (WHO) declared a global pandemic in March 2020. The transmission mechanism of SARS-CoV-2 in indoor environments has begun to be investigated in all aspects. In this regard, many numerical studies on social distancing and the protection of surgical masks against infection risk have neglected the evaporation of the particles. Meanwhile, a 1.83 m (6 feet) social distancing rule has been recommended to reduce the infection risk. However, it should be noted that most of the studies were conducted in static air conditions. Air movement in indoor environments is chaotic, and it is not easy to track all droplets in a ventilated room experimentally. Computational Fluid Dynamics (CFD) enables the tracking of all particles in a ventilated environment. This study numerically investigated the airborne transmission of infectious droplets in a hospital examination room cooled by a split-type air conditioner with the CFD method. Different inlet velocities (1, 2, 3 m/s) were considered and investigated separately. Besides, the hospital examination room is a model of one of the Bursa Uludag University Hospital examination rooms. The patient, doctor, and some furniture are modeled in the room. Particle diameters considered ranged from 2 to 2000 mu m. The evaporation of the droplets is not neglected, and the predictions of particle tracks are shown. As a result, locations with a high infection risk were identified, and the findings that could guide the design/redesign of the hospital examination rooms were evaluated.Publication The Turkish guideline for the diagnosis and management of urticaria-2016(Deri Zührevi Hastalıklar Derneği, 2016-01-01) Goncu, Emek Kocatürk; Aktan, Şebnem; Atakan, Nilgün; Başkan, Emel Bülbül; Erdem, Teoman; Koca, Rafet; Savk, Ekin; Taşkapan, Oktay; Utas, Serap; BÜLBÜL BAŞKAN, EMEL; Tıp Fakültesi; Dermatoloji Ana Bilim Dalı; AAH-1388-2021Background and Design: Albeit an easily recognized disease, urticaria features many diverse approaches which rationalize the need for an algorithm for the diagnosis, classification, etiopathogenesis, diagnostic evaluation and therapeutic approach. Therefore, authors from Dermatoallergy Working Group of the Turkish Society of Dermatology and the Turkish Dermatoimmunology and Allergy Association aimed to create an urticaria guideline for the diagnosis, treatment and follow-up of urticaria.Materials and Methods: Each section of the guideline has been written by a different author. The prepared sections were evaluated in part by e-mail correspondence and have taken its final form after revision in the last meeting held by the participation of all authors.Results: The guideline includes the description, classification, pathophysiology as well as diagnosis and treatment of urticaria. Urticaria is classified into two main types: acute urticaria and chronic urticaria while chronic urticaria is further subdivided into spontaneous urticaria and inducible urticaria. The first step of treatment includes standard doses of H1-blockers. In patients who do not respond to the first step, antihistamine dose is increased up to four times; if unsuccessful, another second-generation antihistamine is given in the same dose. In antihistamine-resistant cases, introduction of omalizumab is required. Omalizumab dose may be increased in patients failing to respond to the standard dose. In patients unresponsive to omalizumab, cyclosporine-A may be given. Routine diagnostic tests are not recommended in acute urticaria. In chronic urticaria, erythrocyte sedimentation rate, differential blood count and C-reactive protein testing are the only investigations that are needed routinely.Conclusion: Chronic urticaria is a disease that can be challenging for the physician in terms of treatment and follow-up. Depending on evidence-based data (and individual experiences), this guideline will have a leading role in the diagnosis and treatment of urticaria and help the physician to overcome the challenges in the management.Publication The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: Real-life experience in Turkey(Dermatovenerological Soc Slovenia, 2018-01-01) Bulur, Isil; Başkan, Emel Bülbül; Özdemir, Mustafa; Balevi, Ali; Goncu, Emek Kocaturk; Altunay, Ilknur; Gonul, Muzeyyen; Ergin, Can; Ertam, İlgen; Erdogan, Hilal Kaya; Bilgin, Muzaffer; Erdem, Mustafa Teoman; BÜLBÜL BAŞKAN, EMEL; Tıp Fakültesi; Dermatoloji Bölümü; AAH-1388-2021Introduction: This study used real-world data to evaluate the effectiveness and reliability of omalizumab in treating recalcitrant chronic spontaneous urticaria in Turkish patients.Methods: Study data were collected retrospectively from eight tertiary-care hospitals in Turkey. This study included 132 patients with chronic spontaneous urticaria that were resistant to H-1 antihistamine treatment in a dose up to four times the licensed dose and were treated with 300 mg/month of omalizumab for 6 months.Results: The mean weekly urticarial activity score (UAS(7)) after omalizumab treatment improved significantly compared to the pretreatment score (p < 0.001). Treatment response was detected primarily in the 1st and 2nd months after treatment. No significant association was observed between omalizumab's treatment effectiveness and disease-related parameters or laboratory data. The mean dermatology life quality index was 23.12 +/- 6.15 before treatment and decreased to 3.55 +/- 3.60 6 months after treatment (p < 0.001). No side effects were reported in 89.4% (118) of the patients.Conclusion: This study showed that UAS(7) decreased significantly and quality of life improved in omalizumab-treated patients. Moreover, treatment effectiveness was mainly observed in the first 2 months after treatment. However, no association was observed between omalizumab treatment effectiveness and disease-related parameters or laboratory data.Publication A report of 13 cases of merkel cell carcinoma: Single-center experience and review of the literature(Korean Dermatological Assoc, 2019-06-01) Yazıcı, Serkan; Yazıcı, Elif Irmak; Adım, Şaduman Balaban; Başkan, Emel Bülbül; Aydoğan, Kenan; Sarıcaoğlu, Hayriye; YAZİCİ, SERKAN; Yazıcı, Elif Irmak; BALABAN ADIM, ŞADUMAN; BÜLBÜL BAŞKAN, EMEL; AYDOĞAN, KENAN; SARICAOĞLU, HAYRİYE; Tıp Fakültesi; Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-1388-2021; AAH-2459-2021; AAH-6216-2021; IHQ-3086-2023; EMN-0789-2022; DPU-8534-2022Background: There is limited data knowledge of Merkel cell carcinoma (MCC) in Turkey aside from a few case reports. Objective: The aim of this study was to describe the clinical characteristics, demographic features, therapeutic parameters, and outcome of primary cutaneous MCC cases from Turkey. Methods: Digital medical records of the 13 MCC patients who were followed-up at a tertiary referral center were retrospectively analyzed. Clinic, demographic, tumor characteristics, and survival of the patients were retrieved. Results: Most of our patients were elderly. Female predominance was noticed. The most common primary site of the tumors was the lower extremities. The overall survival was 42 months, 68% at first year, 68% at third years, and 29% at fifth years. Conclusion: This is the first largest report from Turkish population with female predominance, and lower extremity tendency.Publication Omalizumab versus cyclosporin-a for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?(Wiley, 2019-08-01) Kocatürk, Emek; Engin, B.; Özdemir, Mehmet Akif; Küçük, Özlem Su; Can, Pelin; Örnek, Serdar; Hasal, Eda; Atakan, Nilgün; Baskan, E. B.; BÜLBÜL BAŞKAN, EMEL; Tıp Fakültesi; Deri ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0003-2801-0959; 0000-0002-1140-9261; 0000-0002-9124-5817; AAF-9330-2019; JTD-2412-2023; FZP-3964-2022; BBC-4116-2021; EJK-7570-2022Publication Efficacy of 0.1% tacrolimus ointment in chronic plaque psoriasis: A randomized double-blind placebo-controlled study(Deri Zuhrevi Hastaliklar Dernegi, 2015-01-01) Kaçar, Seval Dogruk; Kaçar, Emre; Baskan, Emel Bulbul; BÜLBÜL BAŞKAN, EMEL; Bolca, Naile; BOLCA TOPAL, NAİLE; Adım, Sadiman Balaban; BALABAN ADIM, ŞADUMAN; Tunalı, Şükran; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; Tıp Fakültesi; Radyoloji Ana Bilim Dalı; JLM-2426-2023; AAH-1388-2021Background and Design: Despite the development of effective systemic treatments and new biological agents for psoriasis nowadays, topical medications are still the mainstay of treatment. Topical calcineurin inhibitors are currently used in various skin diseases. We investigated the efficacy and safety of tacrolimus, which is an alternative in topical treatment, in comparison with the present medications in plaque psoriasis.Materials and Methods: This prospective double-blind placebo-controlled study was conducted in 24 patients with the diagnosis of plaque psoriasis who were seen in Uludag University Hospital dermatology outpatient clinic. 0.1% tacrolimus ointment, 0.1% mometasone furoate ointment, 0.005% calcipotriol ointment and placebo in encrypted bottles were randomly applied under occlusion to 27 psoriatic plaques in test chambers, every other day, for a period of 19 days. Clinic sum scores, side effects, and epidermal thickness measured by superficial ultrasound were noted before and after treatment in all microplaques. Besides, histopathologic scoring and epidermal thickness were measured in 9 patients at the end of the study.Results: The clinic sum scores and ultrasonographic epidermal thickness at the end were both significantly lower than the beginning values in all microplaques (p<0.05). The reduction in these two values with tacrolimus were significantly higher than that with placebo (p<0.001), but no difference was observed with calcipotriol (p=0.287, p=0.813, respectively). On the other hand, the reduction in these values with mometasone was significantly higher than with tacrolimus (p<0.05). Mometasone furoate was the most effective when the three ointments were compared with placebo in terms of total histopathological score and epidermal thickness.Conclusion: Tacrolimus ointment applied under occlusion is an alternative topical medication in the treatment of plaque psoriasis. Occlusion in practice requires patient compliance. Thus, studies to find a new formulation that will increase absorption of drug from thick psoriatic plaques are needed.Publication The effects of topical prophylthiouracyl in plaque type psoriasis: A prospective, double-blind, placebo-controlled study(Türk Sosyoloji Dermatoloji Veneroloji, 2005-01-01) Toker, Semra Çıkman; Sarıcaoğlu, Hayriye; Adım, Şaduman Balaban; Başkan, Emel Bülbül; Karadoğan, Serap Koran; Tunalı, Şükran; Toker, Semra Çıkman; SARICAOĞLU, HAYRİYE; BALABAN ADIM, ŞADUMAN; BÜLBÜL BAŞKAN, EMEL; Karadoğan, Serap Koran; Tunalı, Şükran; Tıp Fakültesi; Patoloji Ana Bilim Dalı; AAH-1388-2021; AAH-6216-2021; CBU-2730-2022; DPU-8534-2022; EMN-0789-2022; GGH-7385-2022Background and Design: Propylthiouracil (PTU) decreases the synthesis of thyroid hormon as well as having immune modulatory and free radical scavenging effects. Oral PTU has been shown to be effective for the treatment of plaque psoriasis in several studies. This study was performed to determine the efficacy of topical PTU in psoriasis.Materials and Methods: Different plaques of 16 patients with plaque psoriasis were treated with 5% topical PTU and placebo, three times daily for 8 weeks in a setting of a double-blind and placebo controlled study. Response to therapy was evaluated by using clinical score, histopathologic score and epidermal thickness.Results: The clinical scores of both PTU and placebo plaques decreased significantly after the treatment (p<0.001). The epidermal thickness of the psoriatic PTU plaques before and after treatment were 0.57 +/- 0.1 mm and 0.46 +/- 0.19 mm, respectively. Furthermore, no significant difference was observed between the pre- and post-treatment histopathological findings of plaques treated with PTU.Conclusion: Topical PTU may be viable steroid-sparing agent, since topical corticosteroid as a conventional agent, have many side effects. Since we didn't observe a significant difference between the plaques treated with PTU and placebo in our group, we concluded that further studies with larger series should be performed to confirm this hypothesis.